Why Patient-Centric Trials Are Easier Said Than Done

In this ISSUE

The VA Gets Real on Reform

The Changing Landscape for Clinical Trial Sites

Creating Medicines 'Appropriate for All'

Industry News

Latest in Business and People News

The latest happenings of the past month in the industry, all in one place.
... /Read more/

Launching Medical Devices in the Japanese Market
- How to navigate regulatory and reimbursement approval
Thursday, October 31, 2019 at 11am EDT

Novartis Data Manipulation Spotlights Wider Concerns

Regulatory enforcement actions, policy updates, and new guidelines show that ensuring the reliability of clinical data is an ongoing priority.
... /Read more/

GrantPlan: Create Grant Budgets with Confidence and Accuracy
Thursday, October 10, 2019 at 11am EDT

Calendar

/ 16^th Annual Patient Summit USA – 10/2-10/3 /

/ Rare Diseases & Orphan Products Breakthrough Summit – 10/21–10/22 /

/ eCOA/ePRO 2019 – 10/29 /

/ Risk-Based Trial Management and Monitoring –11/13–11/14 /

/ Clinical Trial Legal and Contracting Forum – 12/10–12/11 /

Successful Early Phase Drug Development of mAb Drugs
Europe: Thursday, September 26, 2019 at 3pm BST | 4pm CEST
North America: Thursday, October 3, 2019 at 11am EDT | 10am CDT | 8am PDT

Emerging Biopharma Tackles the Opioid Crisis

Dr. Steven Fox, CEO of Akelos Inc., discusses the challenges of developing new non-opioid medical products as the need intensifies and the crisis worsens.
... /Read more/

Begin with the End in Mind: The Strategic Benefit of Coordinating Site Budgeting, Contracting, & Payments
Wednesday, October 2, 2019 at 11am EDT

Opinion

Why Patient-Centric Clinical Trials Are Easier Said Than Done

Michael Keens, COO of Firma Clinical, explores the beginning of patient centricity, common misconceptions related to its implementation, and offers steps to improve the ability to achieve patient centricity within drug development.
... /Read more/

How AI/ML and advanced techniques are enhancing clinical development
Lessons learned from use in study design, patient and site ID, safety, and risk-based monitoring
Tuesday, October 1, 2019 at 11am EDT

Proliferation of Rare Disease R&D Necessitating Novel Strategies

Interest in benchmark data on the scope, performance, and economics of rare disease drug development efforts has grown.
... /Read more/

Ask the editor

Lisa Henderson
Editor in Chief
LHenderson@mmhgroup.com

Advertise

Todd Baker
Group Publisher
tbaker@mmhgroup.com

website / blog / advertise / subscribe